On February 15, 2025, ReShape Lifesciences Inc. entered into a Securities Purchase Agreement to sell 2,575,107 shares and warrants for approximately $6.0 million, closing on February 18, 2025, to fund its merger with Vyome Therapeutics and other corporate purposes.